Job Trends
TScan Therapeutics is looking for strategic partnerships for its heme and autoimmune programs while working to advance two in vivo T cell therapy candidates into investigational new drug–enabling studies.
Labor Market Reports
Job postings increase and competition dips, according to BioSpace data.
Gain the latest insights into the biopharma hiring landscape with BioSpace’s Biopharma Job Market Report Q2 2026. Explore the trends shaping talent acquisition, from rising job postings and sustained R&D hiring to the market activity signaling stronger hiring demand ahead.
Opportunities increased by the end of the first quarter, according to BioSpace data.
Now Hiring
Looking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data. Here are 11 companies with open roles.
Looking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles.
BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.
Career Advice
Funding announcements can signal future hiring activity, giving biotech professionals a chance to build relationships before positions are posted. Industry experts share how to identify the funding events, milestones and company indicators most likely to lead to new jobs.
THE LATEST
The talent pool not keeping pace with increased outsourcing demand is just one reason CDMOs have trouble filling roles, according to a search expert. He also told BioSpace who is most in demand and how candidates can stand out from the competition.
After barely growing in 2024, biopharma employment in Massachusetts dropped 3.1% last year. R&D jobs dipped even more, by 3.9%. Biomanufacturing, however, went up.
Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired by Gilead Sciences and Novartis, respectively.
Biopharma professionals sometimes find themselves out of jobs when employers want to bring staff back into the office, as recently seen at biotech EMD Serono and Exelixis.
Last month, biopharmas cutting or planning to cut their workforces included Amgen, GSK and Novartis, with Novartis’ layoffs affecting the most people.
While biotechs and contract research organizations each have their advantages, that doesn’t mean both options work for everyone. Two experts discuss the differing environments and how to pick between them.
A recruiter and career coach discuss when and why some biotech and pharma professionals put a premium on health insurance benefits.
In addition to laying off employees, including a member of its management team, Lisata Therapeutics is also suing Kuva Labs, alleging the company breached a merger agreement.
So far in 2026, over 50 biopharmas have cut or plan to cut their workforces. If they didn’t take a careful, thoughtful approach to telling people they were being laid off, they likely left a negative impression on employees, based on stories shared with BioSpace.
Biotechs that announced series B financing this year and are looking for employees as they grow include one that received over $100 million and another that has a partnership with a Big Pharma company.